Skip to main content
Equibles
BOLT logo

BOLT · Bolt Biotherapeutics, Inc. · Webcasts, Transcripts & Audio

Track BOLT — free

Use BOLT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BOLT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.45 -0.06 (-1.71%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company believes that this raises substantial doubt about its ability to continue as a going concern within one year after the issuance of the unaudited condensed consolidated financial statements.”
View the 10-Q filed Aug 11, 2026
Market Cap
$6.93M
Shares
1.93M
Volume · Oct 2 885 Avg daily vol (3M) 25.46K

Bolt Biotherapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Bolt Biotherapeutics, Inc. (BOLT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $752,000 −$23.39M '21 Q3 21-12-06 ▲19.7% $2.53M −$16.26M '23 Q3 23-12-06 ▲188.8% $5.27M −$10.81M '24 Q1 24-03-31 ▼76.8% $1.22M −$11.04M '25 Q1 25-05-12 LATEST ▲41.5% $1.80M −$8.56M '25 Q2 25-08-14
Earnings call
FY25 · Q2
2025-08-14
Bolt Biotherapeutics, Inc. (BOLT) Q2 2025 Earnings Call
Revenue
$1.80M
▲ 41.5% YoY
Diluted EPS
$-4.46
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Bolt Biotherapeutics, Inc. (BOLT) Q1 2025 Earnings Call
Revenue
$1.22M
▼ 76.8% YoY
Diluted EPS
$-5.76
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript
Cautious tone BDC-3042 (Dectin-2 agonist) program BDC-4182 (Claudin 18.2 ISAC) program Discontinuation of BDC-1001
Revenue
$5.27M
▲ 188.8% YoY
Diluted EPS
$-5.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q3
2023-12-06
Bolt Biotherapeutics, Inc. (BOLT) Q3 2023 Earnings Call
Revenue
$2.53M
▲ 19.7% YoY
Diluted EPS
$-8.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q3
2021-12-06
Bolt Biotherapeutics, Inc. (BOLT) Q3 2021 Earnings Call
Revenue
$752,000
Diluted EPS
$-12.60
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–5 of 5 webcasts
Key facts CIK 1641281 CUSIP 097702203 Visit website Investor relations